Mutations

COVID shots should target XBB variants in 2023-24 campaign, US FDA staff say COVID-19 vaccines being developed and manufactured for the 2023-2024 campaign should target one of the currently dominant XBB variants, the U.S. Food and Drug Administration's (FDA) staff reviewers said on Monday. Reuters Reuters

...

Bivalent COVID vaccine efficacy at 6 months: 24% against hospitalization, strong against death CIDRAP

Estimated bivalent (two-strain) COVID-19 mRNA vaccine effectiveness (VE) against hospitalization dropped from 62% 1 week after receipt to 24% at 4 to 6 months in adults with healthy immune systems, but protection against severe outcomes was sustained, according to a US Centers for Disease Control and Prevention (CDC) study.

...

Does the end of Covid emergency declarations mean the pandemic is over? What is clear is that Covid isn’t going anywhere, though the damage it is doing to the human species is declining. Helen Branswell STAT

...

There are no fixed borders between a pandemic, when a pathogen is new to humans and causing wide scale disease and often high levels of death, and the ensuing endemic phase, when the disease has settled into something that our immune systems can better cope with, explained Marc Lipsitch, an infectious diseases epidemiologist at the Harvard School of Public Health.

...

Bivalent COVID vaccine shows good Omicron protection while older version wanes CIDRAP

Two studies published today measure the vaccine effectiveness (VE) of COVID-19 vaccines against laboratory-confirmed Omicron variant and subvariants and symptomatic disease. Vaccines that target the newer variants performed well, but primary vaccines offered rapidly waning protection from SARS-CoV-2 infections in the post-Omicron era.